NervGen Pharma Corp. (NGENF)
NGENF Stock Price Chart
Explore NervGen Pharma Corp. interactive price chart. Choose custom timeframes to analyze NGENF price movements and trends.
NGENF Company Profile
Discover essential business fundamentals and corporate details for NervGen Pharma Corp. (NGENF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Apr 2019
Employees
11.00
Website
https://www.nervgen.comCEO
Michael P. Kelly
Description
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
NGENF Financial Timeline
Browse a chronological timeline of NervGen Pharma Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 27 Aug 2025
EPS came in at -$0.10 falling short of the estimated -$0.06 by -73.32%.
Earnings released on 15 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.58%.
Earnings released on 3 Apr 2025
EPS came in at -$0.09 falling short of the estimated -$0.06 by -44.52%.
Earnings released on 14 Nov 2024
EPS came in at -$0.05 falling short of the estimated -$0.05 by -6.24%.
Earnings released on 22 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -24.44%.
Earnings released on 16 May 2024
EPS came in at -$0.03 .
Earnings released on 29 Mar 2024
EPS came in at -$0.11 .
Earnings released on 9 Nov 2023
EPS came in at -$0.05 .
Earnings released on 9 Aug 2023
EPS came in at -$0.06 .
Earnings released on 15 May 2023
EPS came in at -$0.06 .
Earnings released on 27 Mar 2023
EPS came in at -$0.08 .
Earnings released on 14 Nov 2022
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%.
Earnings released on 10 Aug 2022
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%.
Earnings released on 12 May 2022
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%.
Earnings released on 28 Feb 2022
EPS came in at -$0.09 matching the estimated -$0.09.
Earnings released on 18 Nov 2021
EPS came in at -$0.09 falling short of the estimated -$0.07 by -28.57%.
Earnings released on 19 Aug 2021
EPS came in at -$0.06 .
Earnings released on 20 May 2021
EPS came in at -$0.05 .
Earnings released on 8 Apr 2021
EPS came in at -$0.10 .
Earnings released on 30 Sept 2020
EPS came in at -$0.05 .
NGENF Stock Performance
Access detailed NGENF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.